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Summary
Problems with diagnosis and genetic counseling occur
for patients with autosomal recessive proximal spinal
muscular atrophy (SMA) who do not show the most
common mutation: homozygous absence of at least exon
7 of the telomeric survival motor neuron gene (SMN1).
Here we present molecular genetic data for 42 indepen-
dent nondeleted SMA patients. A nonradioactive quan-
titative PCR test showed one SMN1 copy in 19 patients
(45%). By sequencing cloned reverse-transcription (RT)
PCR products or genomic fragments of SMN1, we iden-
tified nine different mutations in 18 of the 19 patients,
six described for the first time: three missense mutations
(Y272C, T274I, S262I), three frameshift mutations in
exons 2a, 2b, and 4 (124insT, 241-242ins4, 591delA),
one nonsense mutation in exon 1 (Q15X), one Alu-me-
diated deletion from intron 4 to intron 6, and one donor
splice site mutation in intron 7 (c.9226TrG). The
most frequent mutation, Y272C, was found in 6 (33%)
of 18 patients. Each intragenic mutation found in at least
two patients occurred on the same haplotype back-
ground, indicating founder mutations. Genotype-phe-
notype correlation allowed inference of the effect of each
mutation on the function of the SMN1 protein and the
role of the SMN2 copy number in modulating the SMA
phenotype. In 14 of 23 SMA patients with two SMN1
copies, at least one intact SMN1 copy was sequenced,
which excludes a 5q-SMA and suggests the existence of
further gene(s) responsible for ∼4%–5% of phenotypes
indistinguishable from SMA. We determined the validity
of the test, and we discuss its practical implications and
limitations.
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Introduction
Autosomal recessive spinal muscular atrophy (SMA) is
a neuromuscular disorder caused by the degeneration of
the anterior horn cells of the spinal cord, which results
in symmetric proximal muscle weakness. Patients with
SMA were classified into three groups according to age
at onset and maximum motor function (International
SMA Consortium 1992; Zerres and Rudnik-Scho¨neborn
1995). Type I SMA (Werdnig-Hoffmann; MIM 253300)
is the most severe form of the disorder, with onset at !6
months of age, inability to sit or walk, and death typ-
ically before the age of 2 years; it is the most common
genetic cause of infant mortality in northern Europeans.
Type II SMA (MIM 253550) is the intermediate form
of the disorder, with onset at !18 months of age; patients
are never able to walk unaided, and life expectancy is
significantly reduced. Type III SMA (Kugelberg-Welan-
der; MIM 253400) is the mildest form of the disorder;
patients are able to walk independently, they often be-
come wheelchair bound during youth or adulthood, and
life expectancy is probably not much reduced. Child-
hood-onset SMA affects ∼1/10,000 newborns, with a
carrier frequency of 1/50.
The SMA region on 5q13 that includes the disease
locus for SMA types I–III shows a complex genomic
structure, including a 500-kb duplication and inversion
(Lefebvre et al. 1995). Four genes, all present in at least
two copies, telomeric and centromeric, have been iden-
tified within the critical region: the survival motor neu-
ron gene (SMN) (Lefebvre et al. 1995), the neuronal
apoptosis inhibitory protein gene (NAIP) (Roy et al.
1995), a subunit of the basal transcription factor
(BTF2p44; Bu¨rglen et al. 1997; Carter et al. 1997), and
a putative RNA-binding protein (H4F5; Scharf et al.
1998). All four genes show homozygous absence of their
telomeric copies in SMA patients, with higher frequen-
cies for SMN1 and lower frequencies for H4F5, NAIP,
and BTF2p44.
The two SMN copies (SMN1 and SMN2) are highly
homologous, displaying only five base-pair differences
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within their 3′ ends (Bu¨rglen et al. 1996a). Two of these
base-pair exchanges, in exons 7 and 8, allow us to dis-
tinguish SMN1 from SMN2 on DNA and RNA level
and are currently used for direct diagnosis of SMA.
Eighty percent to 98% of patients with SMA show ho-
mozygous absence of at least exon 7 of SMN1
(D7SMN1) with slightly higher frequencies in types I and
II than in type III (Bussaglia et al. 1995; Chang et al.
1995; Cobben et al. 1995; Hahnen et al. 1995; Lefebvre
et al. 1995; Rodrigues et al. 1995; Parsons et al. 1996;
Velasco et al. 1996; Simard et al. 1997). Different mech-
anisms, deletions, and gene conversions have been
shown to be responsible for the absence of SMN1 on
SMA chromosomes (Hahnen et al. 1996; van der Steege
et al. 1996; Burghes 1997; Campbell et al. 1997;
DiDonato et al. 1997). Deletions were usually found in
those SMA patients with severe phenotype, whereas gene
conversions resulting in an increase of SMN2 copy num-
ber were usually associated with mild phenotypes. In
rare cases, homozygous absence of SMN1 has been re-
ported in asymptomatic individuals (Cobben et al. 1995;
Hahnen et al. 1995; Wang et al. 1996). Consequently,
doubts about SMN1 as the SMA-determining gene have
arisen but have been eliminated by the identification of
several independent intragenic SMN1 mutations (Bus-
saglia et al. 1995; Lefebvre et al. 1995; Brahe et al. 1996;
Bu¨rglen et al. 1996b; Parsons et al. 1996; Hahnen et al.
1997; McAndrew et al. 1997; Rochette et al. 1997; Tal-
bot et al. 1997; Parsons et al. 1998; Wang et al. 1998).
The SMN protein is ubiquitously expressed, interacts
with several other proteins and itself, and has an essen-
tial role in the spliceosomal snRNP biogenesis (Fischer
et al. 1997; Liu et al. 1997; Lorson et al. 1998). The
identification of several missense mutations has proved
to be very helpful in disclosing the role and function of
the SMN protein. Lorson et al. (1998) have shown that
the self-oligomerization capacity of the SMN protein is
decreased in patients carrying missense mutations in
exon 6 of SMN1.
The finding of intragenic mutations in patients who
retained SMN1 (nondeleted SMApatients) has been con-
siderably improved by the establishment of a PCR-based
quantitative gene dosage test of the SMN1 copy number
prior to mutation analysis (McAndrew et al. 1997;
Rochette et al. 1997). This test allows distinction be-
tween patients with SMA carrying one or more SMN1
copies. On the basis of the high frequency (∼90%) of
homozygous absence of SMN1 exon 7 found in patients
with SMA and according to Hardy-Weinberg equilib-
rium, 99.7% of all patients with SMA must carry at
least one D7SMN1 allele on one chromosome.
McAndrew et al. (1997) found only one SMN1 copy
in 6 (8%) of 76 patients referred as individuals with
potential SMA; in 2 of 6 patients the intragenic muta-
tions were identified. In a second study, in 4 (12%) of
32 patients, one SMN1 copy was identified, and in 2
patients, intragenic mutations were found (Rochette et
al. 1997). In a previous study in which we used SSCP
and subsequent sequence analysis, we found two differ-
ent missense mutations in exon 6 of SMN1 in 3 (13%)
of 23 nondeleted SMA patients (Hahnen et al. 1997).
The question of how many of the typical nondeleted
SMA patients carry intragenic SMN1 mutations is still
unanswered. In this article, we present an analysis of 42
typical patients with SMA who retained at least one
SMN1 copy. A quantitative nonradioactive competitive
PCR showed that 45% of these patients were hetero-
zygous for D7SMN1, and in all cases but one we iden-
tified the mutation. From the practical point of view, the
SMN1 heterozygosity test is an important diagnostic
tool and is essential for risk calculations. We analyzed
73 SMA carriers and 42 homozygously unaffected sibs
of patients with SMA to determine the validity of the
test.
Subjects, Material, and Methods
Patient Samples
All patients fulfilled the diagnostic criteria for prox-
imal SMA defined by the International SMAConsortium
(1992) and Zerres and Rudnik-Scho¨neborn (1995). In-
formed consent was obtained from all subjects. Forty-
two typical patients with SMA (11 type I, 8 type II, and
23 type III) who did not show homozygous absence of
SMN1 exons 7 and 8 were included in this study. Per-
manent lymphoblastoid cell lines were established for
RNA isolation from all patients with one SMN1 copy
(except patient 1006) and from 14 patients with two
SMN2 copies. Some of these patients have been clinically
described in detail (Hahnen et al. 1995, 1997). The mis-
sense mutations T274I and S262I, found in patients
1378, 2549, and 935, have been reported elsewhere
(Hahnen et al. 1997).
Carriers and Noncarriers
Seventy-three carriers (parents of patients with SMA)
in whom de novo mutations could be excluded, either
by family history (multiplex SMA families) or by hap-
lotype analysis with Ag1-CA and C212 and molecular
analysis of SMN as described elsewhere (Wirth et al.
1997), and 42 homozygously unaffected sibs of patients
with SMA, as determined by haplotype analysis includ-
ing Ag1-CA and C212 (Wirth et al. 1995, 1997), were
used to determine the validity of the nonradioactive
quantitative SMN test.
DNA Isolation and Haplotype Analysis
DNA was isolated from blood samples or permanent
lymphoblastoid cell lines by the salting-out method (Mil-
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ler et al. 1988). The multicopy polymorphic markers
Ag1-CA (DiDonato et al. 1994) and C212 (Melki et al.
1994) were used for haplotype analysis as described else-
where (Wirth et al. 1995).
Quantitative Multiplex PCR
The competitive PCR we used is similar to that de-
scribed by McAndrew et al. (1997); however, we mod-
ified it in a few essential points. It is a nonradioactive,
competitive PCR based on different SMN primers: the
forward primer is a mismatch primer that lies adjacent
to the 1-bp exchange in exon 7 (SMN7F: 5′-
CTTCCTTTTATTTTCCTTACAGGGATT-3′) and cre-
ates aHinfI restriction site in SMN1,whereas the reverse
primer lies in intron 7 (SMN7R: 5′-TCCACAAACCA-
TAAAGTTTTAC-3′). The uncut SMN PCR products are
135 bp; SMN2 contains one HinfI recognition site re-
sulting in 101-bp and 34-bp fragments, whereas SMN1
contains two HinfI restriction sites resulting in three
products of 78-bp, 34-bp, and 23-bp fragments after
HinfI digest. Furthermore, we constructed an SMN in-
ternal standard that has a deletion of 21 bp compared
with the genomic fragment and gives two PCR frag-
ments, 91 and 23 bp, respectively, afterHinfI digest. For
the construction of the SMN internal standard, genomic
DNA of an individual who retained only SMN1 was
amplified with the primers SMN7F and SMN7R; 0.5 ml
of this PCR product was reamplified with the SMN7F
and SMN7R-IS (5′-TCCACAAACCATAAAGTTTTA-
CAATGCTGGCAGACTTACTCCT-3′) primers. Subse-
quently, PCR products were cloned into pCRII-TOPO
cloning vector (Invitrogen) according to the supplier’s
protocol and used as SMN internal standard.
The competitive quantitative PCRs were performed in
25 ml reactions that contained 200 ng genomic DNA ,
1 # Cetus PCR-buffer, 200 mM of each dNTPs, 1.5 U
Taq polymerase (Life-Technologies), pg of33.4# 10
each cloned cystic fibrosis transmembrane conductance
regulator (CFTR) internal standard (kindly provided by
T. Prior and A. H. M. Burghes) and SMN internal stan-
dard, 2.5 pmol of each primer CF621F (5′-AGTCAC-
CAAAGCAAGTACAGC-3′) and CF621R (5′-GGGCC-
TGTGCAAGGAAGTGTTA-3′) (Zielinsky et al. 1991),
and 10 pmol of each primer SMN7F and SMN7R. Cy-
cling conditions consisted of an initial denaturation at
94C for 7 min followed by 23 cycles at 94C for 55 s,
51.5C for 55 s, 72C for 1 min, and a final extension
at 72C for 7 min in a Perkin Elmer Cetus Cycler 9600.
The PCR products (10 ml) were digested with 15 UHinfI
(Biolabs) for 3 h at 37C. The samples were run on 10%
native polyacrylamide gels at 8 mA for 3 h and silver
stained as described by Hahnen et al. (1995), followed
by three-dimensional scanning of the gel (BIORAD-im-
aging system) and densitometric analysis with ONE-
Dscan (MWG). The ratios between SMN1/CFTR, de-
fined as standardized SMN1 (SSMN1) values, and
SMN2/CFTR defined as standardized SMN2 (SSMN2)
values, were calculated.
It has to be noted that the CFTR genomic and internal
standard PCR products were not always equal in inten-
sity. However, for correct quantification it is essential to
obtain nearly equal intensities of the two CFTR bands.
In those cases where the CFTR genomic band showed
more than a 30% deviation from the CFTR internal
standard, the PCR was repeated with an amount of ge-
nomic DNA that has been adjusted according to the
percentage of deviation. In most cases this led to satis-
factory results.
RNA Isolation and RT-PCR
RNA was isolated from Epstein-Barr virus trans-
formed lymphoblastoid cell lines by using the TRIzol kit
(Life Technologies). First-strand cDNA synthesis was
performed with oligo-dT primers, 4 mg total RNA and
M-MLV reverse transcriptase (Life Technologies) ac-
cording to the manufacture’s instructions. The single
stranded cDNAs were amplified with 10 ng of each
primer SMN1fwd (5′-ATCCGCGGGTTTGCTATG-3′)
within exon 1 and SMN8rev (5′-TCAACTGCCTCAC-
CACCG-3′) within exon 8, 200 mM each dNTP, 2.8 U
Expand High Fidelity Polymerase (Boehringer) and
1xExpand HF buffer with 15 mM MgCl2. Reactions
were done in 50-ml volumes. PCR conditions included
a 2-min initial denaturation at 94C followed by 30 cy-
cles of 15 s at 94C, 30 s at 67C, and 1 min at 72C.
The elongation time was extended for 20 s in each sub-
sequent cycle, beginning at cycle 11, with a final exten-
sion of 7 min at 72C, in a Perkin Elmer Cetus Cycler
9600.
PCR of Genomic DNA
Genomic DNA of patient 2598 was amplified from
SMN intron 6 to exon 8 as described elsewhere (Hahnen
et al. 1996). The single–base pair differences in exons 7
and 8 were shown by restriction digest PCR-based assay,
as described by van der Steege et al. (1995).
Long-Range PCR
In patients 4259 and 3913, the genomic fragments
including exons 4–8 were amplified with the Boehringer
Expand High Fidelity System by using 250 ng of ge-
nomic DNA and 10 pmol of each primer, SMN4a (5′-
ATCAGATAACATCAAGCC-3′), localized in exon 4,
and 541C1120 (Lefebvre et al. 1995), localized in exon
8. Cycling conditions included a 2-min initial denatur-
ation at 94C followed by 30 cycles of 15 s at 94C, 30
s at 60C, and 8 min at 68C and a final extension of
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30 min at 68C; the elongation time increased by 20 s
per cycle beginning at cycle 11.
Cloning of PCR Products and Sequencing
RT-PCR and genomic PCR products of SMN were
cloned into the pCRII-TOPO cloning vector (Invitrogen)
according to the supplier’s protocol. In general, 10–20
white colonies were analyzed for their SMN1 or SMN2
exon 8 content as described by van der Steege et al.
(1995). Clones containing SMN1 were cultured, and the
DNAwas purified with aminiplasmid kit (Biorad).Cycle
sequencing was performed with the BigDye Terminator
Reaction Kit (PE Applied Biosystems) according to the
manufacturer’s instructions by using vector or internal
primers. The products obtained after cycle sequencing
were purified through Centri-Sep columns (Applied Bios-
ystems). An ABI Prism 377 machine was used for se-
quencing. Each mutation was detected in two indepen-
dent clones; the new mutations were additionally
confirmed by direct sequencing of RT-PCR products of
SMN.
Restriction Digest Assay for Detection of the Y272C
Mutation
For an easy and quick identification of the most fre-
quent missense mutation Y272C (exon 6), we estab-
lished a restriction-based assay of PCR products. The
forward primer (SMN-272F: 5′-TCCCATATGTCCA-
GATTCTC-3′) lies within exon 6; the reverse mismatch
primer (SMN-272R: 5′-TACTTACCATATAATAGCC-
AGTGTGA-3′) lies adjacent to nucleotide exchange
ArG at position 848 in exon 6 and encompasses an
additional 6 bp of intron 6. The Y272C allele creates a
restriction site for Tsp45I that cuts the 101-bp PCR
product into a 75-bp and a 26-bp fragment.
Eighty nanograms of genomic DNA, 10 pmol of each
primer, 120 mM dNTP, 1# Cetus PCR buffer, and 1 U
Taq polymerase (Life-Technologies) were amplified by
means of PCR. Cycling conditions consisted of an initial
denaturation at 94C for 7 min followed by 35 cycles
at 94C for 55 s, 54C for 55 s, and 72C for 1 min,
and a final extension at 72C for 7 min, in a Perkin
Elmer Cetus Cycler 9600. PCR products were purified
through Centri-Sep columns (Applied Biosystems) for
better restriction efficiency. The PCR products were di-
gested with 20 U Tsp45I (Biolabs) for 4 h at 65C. The
samples were separated on 3% (2% NuSieve/1% Aga-
rose) ethidium bromide–stained agarose gels.
Statistical Analysis
Discriminant analysis was used to achieve an optimal
separation of the group of carriers from the group of
noncarriers. Discriminant analysis procedures imple-
mented in the statistical program package SAS were used
(SAS 1996).
The training set for the calibration step of discriminant
analysis consists of 41 noncarriers (controls) and 70 car-
riers. One noncarrier and three carriers were considered
outliers (see validity of the test as discussed later). Be-
cause the densities were not normally distributed in ei-
ther group, a nonparametric approach was taken, and
the performance of classification was evaluated by cross-
validation methods. A minimal error count rate of one
misclassification in both groups was achieved, with a
nearest-neighbor method of ; however, values ofk  4
showed similar results.k ! 8
Results
Establishment of a Nonradioactive Gene Dosage Test
for Determining the SMN1 and SMN2 Copy Number
On the basis of the method described by McAndrew
et al. (1997), we established a nonradioactive quanti-
tative analysis test that enabled us to determine the
SMN1 and SMN2 copy numbers. We amplified exon 3
of CFTR, as genomic control, using the same primers
as reported by McAndrew et al. (1997). For monitoring
the efficiency of the PCR, we used a cloned CFTR in-
ternal standard (kindly provided by T. Prior and A.
Burghes) and an SMN internal standard (see Subjects,
Material, and Methods). In contrast to the methods of
McAndrew et al. (1997), we amplified SMN exon 7 with
a mismatch forward primer that creates a HinfI restric-
tion site in SMN1, whereas SMN2 remains uncut at that
nucleotide position, and a reverse primer localized in
intron 7. In addition, the completeness of the restriction
digest can be monitored by the existence of a further
HinfI restriction site within the genomic SMN PCR
products. This site has been eliminated in the SMN-IS,
but it contains the first restriction site equivalent to
SMN1. Thus, the HinfI restriction–based assay has two
advantages compared with the DraI restriction–based
assay (van der Steege et al. 1995; McAndrew et al.
1997): (1) all SMN-PCR products are cut differently
after HinfI restriction digest, which allows us to rec-
ognize incompletely digested samples; and (2) it is much
less expensive than DraI. The PCR products were sep-
arated on native 10% polyacrylamide gels and visualized
by silver staining. Densitometric measurements of the
gels were scored with the One-Dscan software (MWG)
(fig. 1).
The reproducibility of this modified method was
checked in 10 independent PCR reactions on 10 different
gels by use of DNA from a control with genotype 2/2,
an SMA carrier with genotype 1/2, patients with SMA
(homozygous D7SMN1) with genotype 1/1, and a con-
trol (homozygous D7SMN2) with genotype 1/1. The ge-
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Figure 1 SMN1 dosage analysis in patients, carriers, and controls. Example of a silver-stained PAA gel of the multiplex competitive PCR
of genomic SMN1, SMN2, SMN internal standard, CFTR, and CFTR internal standard (see the Subjects, Material, and Methods section).
notype is defined as the number of marker alleles on
each chromosome and is based on the haplotype analysis
with the multicopy markers Ag1-CA and C212, both
localized at the 5′ end of SMN (for details, see alsoWirth
et al. 1995). The mean SD SSMN1 and SSMN2 values
are given in table 1. DNA from these four individuals
was also used as a reference on all other gels.
Validity of the Heterozygosity SMN1 Test
This test represents a useful molecular genetic tool for
heterozygosity screening in families with SMA as well
as a screening test in the general population. To deter-
mine the validity of the test, we analyzed 73 carriers and
42 homozygously unaffected sibs of patients with SMA.
The SSMN1 values obtained from the quantitative anal-
ysis are presented in figure 2. All but 1 of the 42 non-
carriers presented two SMN1 copies, with SSMN1 val-
ues in the range 0.65–1.33 (mean SSMN1 value SD:
). One of 42 presented three SMN1 copies1.01  0.08
(SSMN1 value 1.61). Among the carriers, three patients
definitively showed SSMN1 values in the interval cor-
responding to two SMN1 copies. The remaining 70 car-
riers showed SSMN1 values between 0.21 and 0.67
(mean SSMN1  SD: ). On the basis of0.40  0.07
this data set, 4 (3.8%) of 115 carriers and noncarriers
showed two SMN1 copies per chromosome.
SSMN1 values of carriers and noncarriers show con-
siderable scatter around their group means. There is a
small region of overlap between both groups and a clear
separation of group means (fig. 2). In a diagnostic sit-
uation, a test item is to be classified into either one of
the two reference groups on the basis of empirical ref-
erence data and appropriate statistical procedures and
interpretation.
Discriminant analysis is among the adequate proce-
dures in situations like this. First, the reference data are
evaluated (calibration step), and second, the test item is
assigned to one or the other group and the uncertainty
of the classification is calculated. However, the deriva-
tion of the optimal discriminant function may not be
trivial. We chose a nonparametric approach and proved
its robustness by extensive evaluations (see Subjects,Ma-
terial, and Methods).
For the critical range of values 0.75  SSMN1 
, the posterior probabilities for classification into0.60
either one group of carriers or noncarriers is given in
table 2. Below and above this range, posterior proba-
bilities are unity and zero, respectively.
Quantitative SMN Analysis and Mutation Analysis in
Nondeleted SMA Patients
Five hundred twenty-five patients with SMAwith typ-
ical SMA features and neurogenic findings on electro-
myogram (EMG) and muscle biopsy were screened for
homozygous absence of SMN1 exons 7 and 8 (table 3).
Eleven (4.1%) of 270 type I, 8 (6.5%) of 124 type II,
and 23 (17.6%) of 131 type III SMA patients retained
at least one SMN1 gene copy. Subsequently, the 42 non-
deleted SMA patients were subjected to a quantitative
analysis of SMN1 and SMN2 copy number analysis.
Nineteen (45.2%) of 42 patients with SMA (6 type I, 6
type II, and 7 type III) showed a gene dosage corre-
sponding to one copy of SMN1, whereas 23 (54.8%) of
42 patients with SMA (5 type I, 2 type II, and 16 type
III) showed a gene dosage corresponding to two SMN1
copies or within the overlapping interval. We assigned
the three patients with SSMN1 values within the over-
lapping region to the group of patients carrying two
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Figure 2 Plot of the SSMN1 values determined in carriers, non-
carriers, and patients with SMA who failed to show homozygous ab-
sence of SMN1. Circles correspond to one SMN1 copy, triangles to
two SMN1 copies, and squares to three SMN1 copies, and the open
rhombus represents the values within the uncertain interval between
one and two SMN1 copies (0.60–0.75). The average values for one
SMN1 and two SMN1 copies are marked with a horizontal line.
Table 1
Reproducibility of SMN1 and SMN2 Copy Number
Subject Genotypea
SSMN1 Values
(mean  SD)
SMN1
Copies
SSMN2 Values
(mean  SD)
SMN2
Copies
Control 2/2 .87  .14 2 1.39  .09 2
Carrier 2/1 .31  .05 1 .82  .08 2
SMA patient (homozygous D7SMN1) 1/1 ) ) .85  .08 2
Control (homozygous D7SMN2) 1/1 .91  .07 2 ) )
a According to Ag1-CA and C212 marker alleles.
SMN1 copies (table 3). Five (22%) of 23 SMA patients
with two SMN1 copies showed homozygous absence of
SMN2 exons 7 and 8 (table 4).
Next we searched for small intragenic mutations
within the SMN1 copy. In 17 of 19 D7SMN1 hetero-
zygous patients with SMA, lymphoblastoid cell lines
were established for RNA isolation. In all patients, we
identified the mutation by sequencing the complete cod-
ing region of SMN1 from cloned RT-PCR products or
by additional analysis of intronic sequences.
In 9 of 17 patients with SMA we identified three dif-
ferent missense mutations: Y272C (5 patients), T274I
(3 patients), and S262I (1 patient), localized in exon 6
(table 4). All three mutations had been reported else-
where (Lefebvre et al. 1995; Hahnen et al. 1997;
McAndrew et al. 1997; Rochette et al. 1997). The fol-
lowing six mutations are described for the first time in
this study.
A nonsense mutation Q15X (exon 1) was found in
two independent type I (3952) and type III (2385) SMA
patients and is caused by a CrT substitution at nucle-
otide 78 that replaces glutamine by a premature stop
codon. This replaces the 294 amino acid SMN protein
by a very short truncated peptide of only 14 amino acids
(fig. 3a).
In patients 19 (type II), 1927 (type III), and 2833 (type
II), we identified three different frameshift mutations
that were caused by a 1-bp insertion ATTCTrATTTCT
at nucleotide 122-124 (exon 2a) designated as 124insT,
a 4-bp insertion ACCTrACGTGTCT at nucleotide 241
(exon 2b) designated as 241-242ins4, and a 1-bp dele-
tion of an A (CAAATrCAAT) at nucleotides 589–591
(exon 4), designated as 591delA, respectively (figs.
3b–3d). All three frameshift mutations lead to premature
stop codons 1, 2, and 26 amino acids, respectively, after
the mutation.
Patients 4259 and 3919, both with type I SMA,
showed an abnormal RT-PCR product of smaller size.
Sequence analysis of SMN1 cDNA clones showed a com-
plete deletion of exons 5 and 6. To determine the exact
breakpoints of the deletion, we performed a long-range
PCR of genomic DNA from exons 4–8 in patient 4249
and his parents (fig. 4a). Two fragments were obtained
in the patient and his father: one of 10 kb, corresponding
to SMN2, and one of 3.4 kb, corresponding to the de-
leted SMN1. By cloning and sequencing the 3.4-kb frag-
ment we identified the deletion breakpoint region be-
tween nucleotides 28621 and 28647 in intron 4 and
between nucleotides 35282 and 35309 in intron 6 (cor-
responding to PAC125D9 sequence in reverted and com-
plemented version; GenBank accession number U80017;
Chen et al. 1998), which resulted in a 6.6-kb deletion
that encompasses complete exons 5 and 6, intron 5, and
part of introns 4 and 6. Both breakpoint ends lie within
Alu-repetitive elements that share 82% identity between
nucleotides 28544 and 28711 in intron 4 and nucleo-
tides 35205 and 35372 in intron 6 and show a 100%
identical 27-bp deletion breakpoint region (fig. 4b). Both
Alu repeats are oriented 3′–5′. The 26-bp core Alu se-
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Table 2
Posterior Probabilities for Classification into the Carrier or
Noncarrier Group
Test Value
of SSMN1
Classified
into Group
Posterior
Probability
Carrier
Posterior
Probability
Noncarrier
.60 Carrier 1.0000 .0000
.61 Carrier .7455 .2545
.62 Carrier .7009 .2991
.63 Carrier .6373 .3627
.64 Carrier .6373 .3627
.65 Carrier .6373 .3627
.66 Noncarrier .4677 .5323
.67 Noncarrier .3694 .6306
.68 Noncarrier .3694 .6306
.69 Noncarrier .3694 .6306
.70 Noncarrier .3694 .6306
.71 Noncarrier .2265 .7735
.72 Noncarrier .1633 .8367
.73 Noncarrier .1633 .8367
.74 Noncarrier .1277 .8723
.75 Noncarrier .0000 1.0000
NOTE.—Based on nonparametric discriminant analysis with prior
probabilities of .50 (SAS Program; see Subjects,Material, andMethods
section).
quence responsible for homologous and nonhomologous
recombinations (Ru¨diger et al. 1995) is localized 4 bp
upstream of the 27-bp deletion breakpoint region. This
is the first Alu-mediated large deletion within SMN1
identified so far.
Sequencing of SMN1 RT-PCR products from patient
2598 showed no full-length SMN1, but only the isoform
D7SMN1 cDNA, which indicates that a splice site mu-
tation or deletion of exon 7 must have occurred. PCR
amplification of genomic DNA from intron 6 to exon
8, followed by cloning and sequencing of SMN1 clones,
disclosed a TrG nucleotide exchange at position 6
within the intron 7 donor splice site (c.9226TrG; fig.
3e).
For patients 1006 and 4133, no RNA was available;
SSCA of each SMN exon in patient 1006 failed to show
any aberrant band. Haplotype analysis in the family of
patient 4133 displayed the same haplotype for Ag1-CA
and C212 as found for the other five patients carrying
the missense mutation Y272C (table 4). Because of the
high frequency of this mutation, we established a PCR-
based assay by using a mismatch primer that allows easy
detection of this mutation (see Subjects, Material, and
Methods). Patient 4133 showed the typical pattern for
patients or carriers with the Y272C mutation (fig. 5). In
summary, nine different mutations in 18 unrelated pa-
tients with SMA were found: three missense mutations,
Y272C (6 patients), T274I (3 patients), and S262I (1
patient); one nonsense mutation Q15X (2 patients);
three frameshift mutations, 124insT (1 patient), 241-
242ins4 (1 patient), and 591delA (1 patient); one de-
letion of exons 5 and 6 (2 patients); and one splice site
mutation, c.9226TrG (1 patient).
Sequence Analysis of SMN1 in Patients with SMA with
Two SMN1 Copies
Twenty patients with typical SMA each had two
SMN1 copies. In three further cases (2544, 1377, and
2245), the SSMN1 values lie within the overlapping in-
tervals. Although it is very unlikely that these SMA pa-
tients, all but one of whom have nonconsanguineous
parents, have 5q-unlinked SMA, we decided to sequence
SMN1 to eliminate any doubt concerning a possible case
with two subtle mutations. RNA was available from 14
of 23 patients, which allowed us to sequence at least
one copy of the complete coding region of SMN1. These
14 patients also include patients 2544 and 2245 (with
values within the overlapping interval) and all patients
with homozygous deletions of SMN2. In all cases we
identified an intact SMN1 (table 4). In addition, in four
families, a second unaffected sib showed identical hap-
lotypes within the SMA region, compared with the af-
fected sib. In all cases in which DNA from parents was
available for testing, two SMN1 copies were found. All
together, these findings give strong evidence of the ex-
istence of gene(s) responsible for ∼4%–5% of pheno-
types indistinguishable from SMA.
Correlation of Intragenic SMN1 Mutations, SMN2
Copy Number, and Severity of SMA
To look for evidence of founder mutations, we per-
formed haplotype analysis with the multicopy markers
Ag1-CA and C212 and determined the parental origin
of the subtle mutation by quantitative analysis of SMN1
in the parents (table 4). In all 17 of 19 cases in which
the parents were available, one parent was D7SMN1
heterozygous and the other had two SMN1 copies,
which indicates that the latter parent must be the carrier
of a subtle mutation. In each case in which identical
mutations were identified in at least two independent
patients, these were found on identical haplotypes, pro-
viding evidence of founder mutations (table 4). The mis-
sense mutation Y272C was found in 6 (33%) of 18
patients, representing the most frequent intragenic mu-
tation. It was identified in all three types of SMA and
was always present on the same haplotype: 28/29 alleles
for C212 and 108/112 alleles for Ag1-CA. The consen-
sus haplotypes for the other mutations are given in table
4.
To answer the question whether the severity of SMA
in patients with identical intragenic mutations but dif-
ferent phenotypes is influenced by the SMN2 copy num-
ber, we also determined the number of SMN2 copies. In
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Table 3
Total No. and Frequency of Mutations Found in Patients with Type I, Type II, or Type III SMA
No. (%) of SMA Patients
SMA
Type
No. of
Patients
Homozygous
for D7SMN1
Nondeleted
SMA
Heterozygous
for D7SMN1
With at Least
Two SMN1 Copies
With Subtle
Mutations
in SMN1
With at Least
One D7SMN1
With Mutations on
Both Chromosomes
I 270 259 (96) 11 (4.1) 6 (2.2) 5 (1.9) 6 (2.2) 265 (98.1) 265 (98.1)
II 124 116 (93.5) 8 (6.5) 6 (4.8) 2 (1.6) 6 (4.8) 122 (98.4) 122 (98.4)
III 131 108 (82.4) 23 (17.6) 7 (5.3) 16 (12.2) 6 (4.6) 115 (87.8) 114 (87)
Total 525 483 (92) 42 (8) 19 (3.6) 23 (4.4) 18 (3.4) 502 (95.6) 501 (95.1)
the six patients who carry the Y272C mutation, there
were two SMN2 copies for patients with type I SMA
(patients 1307, 1023, 3551), two and three SMN2 cop-
ies for type II SMA (patients 44 and 4133, respectively),
and three SMN2 copies for type III SMA (patient 1030),
which indicates that this is a severe mutation and that
the severity of SMA is influenced by the SMN2 copy
number. The T274I mutation was found in one patient
with type II (patient 1378) and two patients with type
III SMA (patients 2549 and 2692), with one SMN2 copy
in patients with type II and two SMN2 copies in patients
with type III. Thus, patient 1378 has type II SMA despite
carrying only one SMN2, whereas patients 2549 and
2692 developed type III SMA in the presence of only
two SMN2 copies, which indicates that T274I is a mild
mutation. Similarly, patient 935, with the missense mu-
tation S262I, has type III SMA even in the presence of
only one SMN2, which indicates that this is a very mild
mutation.
Patients 4259 and 3919, with SMN1 mutations en-
compassing larger deletions (exons 5 and 6), and patient
3952, with a nonsense mutation in exon 1 (Q15X), de-
veloped type I SMA in the presence of two SMN2 copies,
which indicates that this mutation acts similar to a de-
letion of the complete SMN1. However, patient 2385,
who carries the same nonsense mutation (Q15X),
showed three or four SMN2 copies and thus developed
type III SMA. Patient 2598, with the splice site mutation
in intron 7, shows a type III SMA in the presence of two
SMN2 copies, which suggests that the skipping of SMN1
exon 7 only is a mild mutation.
These data clearly show that the severity of the phe-
notype is determined by the mutations from both hom-
ologs and the SMN2 copy number. Nevertheless, two
multiplex families, the first with three affected brothers
and the genotype Y272C/D7SMN1 and the second with
two affected brothers and the genotype T274I/D7SMN1,
showed the same number of SMN2 copies despite phe-
notypic discrepancies, types IIIa and IIIb (table 5). Ac-
cording to Zerres and Rudnik-Scho¨neborn (1995) pa-
tients with type IIIa SMA have an age at onset of !3
years, and patients with type IIIb SMA, 13 years, the
latter showing a mild course with a high probability of
remaining ambulant for decades. This suggests that the
severity of SMA is also influenced by factors still
unknown.
Identification of a De Novo Gene-Conversion Event by
Quantitative Analysis of SMN Gene Copies
In a previous study we reported a 2% de novo mu-
tation frequency in patients with SMA (Wirth et al.
1997). In all but one family, we identified a paternal
origin of the de novo mutation by haplotype analysis
with the multicopy markers Ag1-CA and C212, which
showed paternal allele loss of these markers. In one case,
family G, the only difference between the affected and
unaffected haploidentical sibs is the homozygous ab-
sence of SMN1. We concluded that a gene-conversion
event is responsible for the de novo mutation. By quan-
titative analysis we were now able to show that the un-
affected brother carries two SMN2 copies besides one
SMN1 copy, whereas his affected brother carries three
SMN2 copies, which indicates that SMN1 has been con-
verted into SMN2. Furthermore, we determined the pa-
rental origin of the de novomutation.Whereas the father
carries one SMN1, the mother has two SMN1 copies,
which indicates that the de novo mutation must be of
maternal origin. Finally, we confirmed the paternal or-
igin of the de novo mutation in the other six families
reported elsewhere (Wirth et al. 1997). In all six families,
the fathers carried two SMN1 copies, whereas the moth-
ers had only one SMN1 copy.
Discussion
Quantitative SMN1 Analysis in Nondeleted SMA
Patients
It is now well known that homozygous absence of at
least exon 7 of SMN1 is the major defect in patients
with SMA. Overall, the deletion frequency is in the range
92%–100% in type I, 82%–100% in type II, and
78%–100% in type III (Bussaglia et al. 1995; Chang et
al. 1995; Cobben et al. 1995; Hahnen et al. 1995; Le-
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Table 4
Quantitative, Mutation, and Haplotype Analysis in Nondeleted Type I, Type II, or Type III SMA Patients
Patient
Sex
DNA
Number
SMA
Type
SSMN1
Value
SMN1
Copies
SSMN2
Value
SMN2
Copies
Type of
Mutationa Mutation
Haplotype
Parental
Origin of
Mutations FHb
C 212
(P/M)
Ag1-CA
(P/M)
1, F 1307 I .40 1 1.15 2 Missense Y272C 31–28 29 102–108 112 M 0/1/0
2, F 1023 I .39 1 1.10 2 Missense Y272C 28 29–25 108 112–114 P 0/2/0
3, M 3551 I .46 1 1.29 2 Missense Y272C 28 29–34 108 112–106 P 0/0/0
4, F 44 II .34 1 1.46 2 Missense Y272C 28 29–29 108 112–110 P 1/0/0
5, M 4133 II .43 1 1.59 3 Missense Y272C 27 29–28 29 114 116–108 112 M 0/0/0
6, M 1030 III .35 1 2.06 3 Missense Y272C 28 29–29 30 108 112–110 P 2/2/0
7, M 1378 II .40 1 .61 1 Missense T274I del –25 29 del –108 114 M 2/0/0
8, M 2549 III .33 1 1.09 2 Missense T274I 32–25 29 100 108 114 M 1/0/0
9, M 2692 III .32 1 1.03 2 Missense T274I 25 29 28 108 114 104 NA 0/0/0
10, M 935 III .42 1 .54 1 Missense S262I 27–33 110–102 P 0/1/0
11, F 3952 I .35 1 1.05 2 Nonsense Q15X 34–27 28 106–114 118 M 0/0/0
12, F 2385 III .33 1 1.80 3 Nonsense Q15X 27 28 29 108 110 114 118 NA NA
13, M 19 II .44 1 1.19 2 FS 124insT 29–24 31 108 114–100 112 M 0/0/0
14, M 1927 III .40 1 1.83 3 FS 241-242ins4 29 30–22 30 108 110–114 P 1/1/0
15, F 2833 II .36 1 1.13 2 FS 591delA 29 31 33 34 106 106 108 NA 1/0/0
16, F 4259 I .41 1 1.17 2 Deletion Exons 5/6 28 30–32 108 108–100 P 0/0/0
17, M 3919 I .23 1 1.48 3 Deletion Exons 5/6 28 30–26 28 108 108–108 112 P 0/0/0
18, F 2598 III .36 1 1.29 2 Spl site c.9226TrG 32–28 29 102–110 114 M 0/0/0
19, M 1006 II .35 1 1.50 3 RNA NA ) 28 30–29 31 108 112–108 116 M 0/1/0c
20, M 3612 I–II 1.02 2 del ) ) None 34 26 30 108 108 112 ) 0/0/0
21, M 2395 III .98 2 del ) ) None 27–28 114–112 ) 0/1/1
22, M 2161 III 1.07 2 del ) ) None 30 27–27 114–108 112 ) 0/1/0
23, M 2544 III .62 1/2 del ) ) None 27 28 30 108 114 118 ) NA
24, F 2128 III .78 2 del ) ) None 29–34 108–106 ) 0/1/1d
25, M 1058 I .96 2 .65 1 ) None 26 28–28 108 116–112 ) 0/1/1
26, M 1377 I .68 1/2 .45 1 ) ND 30–25 29 108–114 ) 0/1/0
27, F 621 I .77 2 1.05 2 ) ND 29–28 30 110–108 114 ) 0/1/1
28, M 1151 I 1.12 2 .80 2 ) ND 28 30–27 108 114–112 ) 0/1/0
29, F 2192 I .80 2 .58 1 ) ND 27 30 32 35 100 102 108 112 ) NA
30, M 751 II 1.10 2 .62 1 ) ND 29–23 28 112–114 ) 0/1/0
31, M 968 III .90 2 .68 1 ) None 29 32 34 106 112 - NA
32, M 2869 III .99 2 1.30 2 ) ND 24 26 27 28 108 110 114 ) NA
33, F 938 III .89 2 1.15 2 ) ND 28 29–24 27 108 116–108 114 ) 0/3/0
34, M 2436 III .86 2 .49 1 ) None 31 32–23 25 100 106–108 114 ) 0/0/0
35, M 3488 III .90 2 1.00 2 ) None 26 27 28 108 114 114 ) 0/0/1
36, F 2495 III .93 2 .53 1 ) ND 23 24 26 102 110 112 ) 0/0/0
37, M 2188 III .97 2 1.21 2 ) None 34 36–26 28 100 106–112 ) 0/0/0
38, M 2245 III .73 1/2 .40 1 ) None 24 27 32 36 102 106 110 112 ) NA
39, F 1514 III 1.17 2 .46 1 ) ND 31 33 34 35 102 106 108 110 ) NA
40, M 2272 III 1.07 2 .70 1 ) None 27 28 33 102 108 114 ) NA
41, M 235 III .80 2 .59 1 ) None 27 29 29 108 114 116 ) NA
42, M 3630 III .90 2 1.88 3 ) None 32 32 32 32? 106 106 106 106? ) NA
NOTE.—NA  not available, ND  not determined, P  paternal, and M  maternal. Haplotype carrying the intragenic mutation is marked
with underlined allele numbers.
a FS  frameshift, and Spl site  splice site.
b FH  family history. Data are no. of haploidentical affected siblings/no. of nonhaploidentical unaffected siblings/no. of haploidentical
unaffected siblings.
c Pseudodominant family, affected father.
d Consanguineous family.
febvre et al. 1995; Rodrigues et al. 1995; Parsons et al.
1996; Velasco et al. 1996; Simard et al. 1997). These
discrepancies may be partly due to different ethnic origin
and partly to misdiagnoses but are essentially due to
true differences between the three SMA phenotypes.
McAndrew et al. (1997) and Rochette et al. (1997) re-
cently suggested use of the quantitative analysis of
SMN1 for determining D7SMN1 heterozygous patients
before performing intragenic mutation analysis. Both ar-
ticles reported analysis of patients who were referred for
routine diagnosis without being sufficiently investigated
clinically. Consequently, they found one SMN1 in only
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Figure 3 New intragenic SMN1 mutations in patients with SMA. Mutant sequences of patients (upper) a, 3952; b, 19; c, 1927; d, 2833;
e, 2598; and control sequences (lower) are shown. Arrows indicate the positions of the mutations. Bars indicate exon-intron boundaries.
6 (8%) of 76 (McAndrew et al. 1997) and 4 (12%) of
32 (Rochette et al. 1997), and in 3 of 6 and 2 of 4
intragenic mutations, respectively.
To obtain reliable data concerning the frequency of
intragenic mutations among nondeleted SMA patients,
we included in this study only patients with well-char-
acterized SMA with typical features of proximal SMA,
which was supported by EMG and muscle biopsy find-
ings. The distribution of patients without the deletion
among the three types of SMA in this study is 4.1% type
I, 6.5% type II, and 17.6% type III SMA (table 3) and
corresponds to our previously reported frequencies of
nondeleted SMA patients (Hahnen et al. 1995). In con-
trast to the low frequency of heterozygous SMA patients
identified by McAndrew et al. (1997) and Rochette et
al. (1997), we determined a heterozygous D7SMN1
status (one SMN1 copy) in 45.2% of nondeleted SMA
patients (six type I, six type II, and seven type III). Fur-
thermore, our data show that quantitative analysis fol-
lowed by sequencing of the complete coding region is
very efficient and allows the identification of almost all
mutations (18 of 19). The only D7SMN1 heterozygous
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Figure 4 Alu-mediated deletion in patient 4259 with SMA. A, Long-range PCR products between exons 4 and 8 from father (F), mother
(M), and patient (P) were separated on ethidium bromide–stained agarose gels. The normal, full-length SMN-PCR product is 10 kb, whereas
the deleted product is 3.4 kb. The size marker is the 1-kb ladder (MBI-Fermentas). B, Sequence homology of the Alu-repetitive elements in
introns 4 and 6 to the junction fragment of patient 4259 is shown. The deletion breakpoint region is marked with a gray box; the 26-bp core
sequence is written in italics and bold letters.
SMA patient (patient 1006) in whom we did not identify
the mutation is the son of an affected father, who showed
homozygous absence of SMN1; therefore the son is an
obligate carrier of D7SMN1. In addition, because no
RNA was available, the result is not conclusive.
In a previous study, we analyzed 23 patients with typ-
ical SMA by SSCA of each exon, followed by sequencing,
and identified the mutation in 3 (13%) of 23 patients
(Hahnen et al. 1997). The actual study led to the iden-
tification of mutations in six other patients of the same
cohort. None of the mutations was a deletion or inver-
sion of a complete exon. This clearly shows the limi-
tations of SSCA compared with direct sequencing. Be-
cause the assignment of the mutation requires the
sequencing of cloned SMN1 gene products and because
the coding region of SMN1 is small (!1 kb), it is far
more sensible to perform sequencing directly instead of
performing SSCA after the quantitative analysis.
The percentage of subtle mutations, 3.4%, can now
be added to the percentage of homozygous absence of
SMN exon 7, so that mutations on both chromosomes
are found in 95.1% of patients with SMA (98.1% type
I, 98.4% type II, and 87% type III) (table 3). On the
basis of a heterozygosity frequency of 1:50 for an SMA
mutation in the general population, the frequency for a
subtle mutation is ∼1:3,000, which would account for
an incidence of ∼1:35,000,000 for SMA with two subtle
mutations.
Evidence for SMN1-Unlinked SMA Patients
Twenty-three patients with typical SMA showed two
SMN1 copies, which suggests an SMN1-unlinked SMA.
All but 1 of the 23 SMA patients with two SMN1 copies
were derived from nonconsanguineous families, which
makes the existence of intragenic mutations on both
chromosomes extremely unlikely. Four of 23 patients,
including the 1 from the consanguineous family, have 1
unaffected haploidentical sib. A homozygous absence of
SMN2 was found in 5 (22%) of 23 patients compared
with only 3%–4% in the normal population. However,
this proportion may be biased and caused by our special
attention given to patients carrying homozygous absence
of SMN2 during the collection process of patients with
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Figure 5 Restriction digest PCR-based assay for detection of the
Y272C mutation. PCR product obtained from DNA of patient 3551,
who carries the Y272C mutation, are cut with Tsp45I into 75-bp and
26-bp fragments; individuals without this mutation show a 101-bp
uncut PCR fragment on a 3% ethidium bromide–stained agarose gel.
SMA in the past few years. The sequencing results of
the complete coding region of the SMN1 gene in 14 of
23 patients (including the 5 patients with homozygous
absence of SMN2) showed an intact SMN1 gene in each
case. Furthermore, on the basis of our actual knowledge
concerning the essential function of SMN in spliceoso-
mal snRNP biogenesis (Fischer et al. 1997; Liu et al.
1997), the findings that the absence of SMN in knockout
mice is lethal in the early embryonic state (Schrank et
al. 1997) and that homozygous absence of both SMN1
and SMN2 has never been observed, obviously being a
lethal state, indicate that patients with homozygous ab-
sence of SMN2must have at least one functional SMN1.
This suggests that, in as little as 4%–5% (1.9% type I,
1.6% type II, and 13% type III) of all patients with SMA,
gene(s) other than SMN1 are very likely responsible for
the SMA phenotype. We can speculate, on the basis of
these findings, that other genes encoding SMN-interact-
ing proteins, such as SIP1 and other not-yet-character-
ized proteins (Fischer et al. 1997; Liu et al. 1997), may
be responsible for an SMA-like phenotype.
Intragenic SMN1 Mutations
In 18 of 19 heterozygous D7SMN1 patients, we iden-
tified nine different intragenic mutations, six of which
were new. In more than half of the cases (10 of 18), we
identified three different missense mutations, Y272,
T274I, and S262I, that have been reported elsewhere in
single cases (Lefebvre et al. 1995; Hahnen et al. 1997;
McAndrew et al. 1997; Rochette et al. 1997). All three
mutations are localized within exon 6 and affect the
SMN-SMN oligomerization capacity (Lorson et al.
1998). The nonsense mutation, Q15X, and the three
frameshift mutations, 124insT, 241-242ins4, and
591delA, lead to SMN-truncated products of various
lengths and thus to nonfunctional SMN1 proteins.
Here we present the first Alu-mediated deletionwithin
SMN1 in two independent patients with SMA. It has
been shown that Alu repeats are five times more abun-
dant within a 131-kb region that encompasses SMN and
NAIP than in genomic DNA in general (Chen et al.
1998). Alu repeats are frequently responsible for aber-
rant recombination leading to deletions, duplications, or
inversions (Ru¨diger et al. 1995). Ru¨diger et al. (1995)
have found that a 26-bp core sequence within the Alu
repeat, which is highly conserved and shows homology
to the 8-bp x sequence known to stimulate recBC-me-
diated recombination in prokaryotes, is a hot spot of
recombination in several disease genes. We have shown
that the two Alu repeats in introns 4 and 6 (the deletion
occurred between these two introns) were 86% homol-
ogous, both oriented 3′–5′, and that the deletion break-
point region lies a few base pairs upstream of the 26-
bp Alu core sequence. This finding is in agreement with
the observation described for other disease genes, such
as the a-globin gene cluster (Harteveld et al. 1997), he-
reditary nonpolyposis colon cancer (Nystro¨m-Lahti et
al. 1995), BRCA1 (Petrij-Bosch et al. 1997), and others,
that Alu-mediated deletions occur near or at the core
sequence. Alu-mediated deletions and duplications
might be a frequent phenomenon in SMA, although this
has not yet been reported. The existence of two highly
homologous SMN copies, the variability in SMN copy
number, and the lack of sequence discrepancies from
exon 1 to intron 6 hamper the identification of deletions,
duplications, and their breakpoints.
Here we present a splice site mutation that occurred
within the donor splice site consensus sequence of intron
7 at position 6 (TrG) and resulted in SMN1 tran-
scripts lacking exon 7 (for further details see Lorson et
al. [in press]). Two further splice site mutations caused
by deletions in the acceptor splice site (c.868-10del7)
and in the donor splice site (c.9223del4) of exon 7
have been reported (Lefebvre et al. 1995). This splice
site mutation in patient 2598 that produces D7SMN1
transcript only confers further evidence for the func-
tional relevance of SMN1 exon 7.
Genotype-Phenotype Correlation
The severity of the SMA phenotype is dependent on
the mutations on both chromosomes (intragenic muta-
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Table 5
Quantitative and Haplotype Analysis in Two Families with Siblings with Discordant SMA Phenotypes and Intragenic Mutations
Family
and DNA
Number Sex
SMA
Type Genotype
Age
Motor
Milestones
(age [years])
SSMN1
Value
SMN1
Copies
SSMN2
Value
SMN2
Copies
Current
(years)
At
Onset
(years)
At
Diagnosis
(years)
244:
1029 M IIIa D7SMN1/Y272C 35 1.4 2.8 Wheelchair (26) .27 1 1.83 3
1030 M IIIb D7SMN1/Y272C 31 5 10 Still walking .35 1 2.06 3
1019 M IIIb D7SMN1/Y272C 39 16 18 Still walking .21 1 1.83 3
614:
2593/B1 M IIIa D7SMN1/T274I 20 1.4 2.8 Wheelchair (5) .40 1 1.28 2
2549 M IIIb D7SMN1/T274I 24 3.5 4.1 Wheelchair (16) .33 1 1.09 2
tion D7SMN1 caused either by deletion or gene con-
version of SMN1) and by the total number of SMN2
copies. Four of the subtle mutations (Y272C, T274I,
Q15X, and the Alu-mediated deletion of exons 5 and
6) were found in at least two independent patients with
SMA, always on the same haplotype background, which
indicates that they are founder mutations. The most
abundant mutation, Y272C, was found in 6 (33.3%) of
18 independent patients with SMA types I–III. This mu-
tation has been reported previously in two patients with
type I SMA (Lefebvre et al. 1995; Rochette et al. 1997).
Similar to the patient with type I SMA reported by Roch-
ette et al. (1997), the three patients with type I SMA
presented here carry two SMN2 copies, whereas the pa-
tient with type III SMA carries three SMN2 copies and
the two patients with the intermediate form carry two
and three SMN2 copies, which confirms the role of
SMN2 in modulating the SMA phenotype (Lefebvre et
al. 1995; Burghes et al. 1997; Campbell et al. 1997;
McAndrew et al. 1997). However, the correlation is not
absolutely linear, suggesting that other factors may also
modulate the SMA phenotype. These data also show
that Y272Cmust be a severe mutation, which is in agree-
ment with results presented by Lorson et al. (1998), who
showed that SMN1 protein containing the Y272C mu-
tation leads to almost complete reduction of the self-
oligomerization capacity.
Compared with the patients carrying the Y272C mis-
sense mutation, where the presence of two SMN2 copies
was found in type I SMA, the three patients with the
T274I mutation developed type II SMA with one copy
of SMN2 and type III with two copies of SMN2, which
suggests that T274I is a mild mutation. The S262I mu-
tation seems to be an even milder mutation, because
patient 935, carrying this mutation, developed type III
SMA in the presence of only one additional SMN2 copy.
This is in agreement with the finding of Lorson et al.
(1998), who showed that T274I and S262I lead to minor
reduction of the self-oligomerization capacity of the
SMN protein.
The two patients with Alu-mediated deletion includ-
ing exons 5 and 6 of SMN1, and the one patient with
nonsense mutation in exon 1 (Q15X), developed type I
SMA in the presence of two SMN2 copies, which in-
dicates that SMN1 is, in both cases, as expected, non-
functional. However, patient 2385, who carries the same
nonsense mutation (Q15X), shows three or four SMN2
copies and has type III SMA. Patient 2598, with the
donor splice site mutation in intron 7 of SMN1, has type
III SMA in the presence of only two SMN2 copies, which
suggests that this mutation is a mild one. This is in agree-
ment with the SMN self-oligomerization results obtained
for D7SMN isoforms (Lorson et al. 1998). Finally, two
of the patients with frameshift mutations developed type
II SMA in the presence of two SMN2 copies, whereas
the third patient with a frameshift mutation developed
type III SMA in the presence of three SMN2 cop-
ies—again showing the role of SMN2 as a modifier of
the severity of SMA.
We also observed in two multiplex families intrafam-
ilial discrepancies of SMA IIIa and IIIb, despite the fact
that the sibs showed identical haplotypes and carried the
same number of SMN2 copies. This observation is in
agreement with previous reports of affected and unaf-
fected or phenotypically discordant haploidentical sibs
that also suggested that factors other than SMN2 copy
number can modulate the SMA phenotypes (Cobben et
al. 1995; Hahnen et al. 1995; Wang et al. 1996;
McAndrew et al. 1997). In conclusion, the genotype-
phenotype correlation studies of these patients clearly
showed that the severity of SMA is determined by the
SMN1 mutations on both chromosomes, the SMN2
copy numbers, and additional unknown factors.
Identification of a De Novo Gene-Conversion Event
Gene conversion has been postulated as a major mu-
tational mechanism in SMA, leading to a replacement
of SMN1 by SMN2 (Cobben et al. 1995; Hahnen et al.
1996; Burghes et al. 1997; Campbell et al. 1997;
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DiDonato et al. 1997). De novo gene-conversion events
in human genes have been described only twice before:
21-hydroxylase (Collier at al. 1993) and A g-globin gene
(Patrinos et al. 1998). Here we reanalyzed a family (G)
with two sibs, one affected and one unaffected, showing
identical haplotypes for all tested markers (Wirth et al.
1997). The only difference we found was the homozy-
gous absence of SMN1 in the affected sib, which must
have occurred as a de novo event. Quantitative analysis
showed a higher SMN2 copy number in the affected
child compared with the unaffected sib, providing evi-
dence of a gene conversion of SMN1 in SMN2.
The gene dosage test is also useful for the identification
of de novo mutations, especially when linkage analysis
remains inconclusive or no further sibs are available. We
have previously reported de novo rearrangements in 7
(2%) of 340 patients with SMA (Wirth et al. 1997). In
all but one case, we determined a paternal origin of the
de novo rearrangements by finding allele loss of markers
Ag1-CA and C212; in the remaining case (family G),
the parental origin of the de novo mutation could not
be identified, because no allele loss occurred. The quan-
titative SMN1 analysis allowed the determination of a
maternal origin of this de novo mutation. It is the second
de novo mutation of maternal origin (Raclin et al. 1997).
Practical Implications and Limitations of the SMN1
Heterozygosity Test
First, from the practical point of view, the SMN1 het-
erozygosity test is chiefly an important diagnostic tool
for nondeleted SMA patients. Our test showed that
45.2% of nondeleted SMA patients with clinically well-
defined type I–III SMA were heterozygous for D7SMN1,
and, in all but one patient, an obligate carrier for whom
no RNA was available, we identified intragenic SMN1
mutations. This means that the heterozygosity test helps
to confirm the diagnosis of SMA in patients with one
SMN1 copy. Consequently, a further search for the exact
mutation can eventually be omitted in the routine di-
agnosis, because of high costs and labor-intensive pro-
cedures, and replaced by haplotype analysis for risk cal-
culations. This strategy can be followed only when the
SMA phenotype of the patient has been carefully inves-
tigated. Parsons et al. (1998) concluded that some of the
patients referred to their laboratory for SMA testing
without sufficient clinical investigation may be carriers
by chance and may have neuromuscular disorders other
than SMA. Second, the heterozygosity testing is essential
for calculating risk of heterozygosity in the following
groups: parents of patients with SMA where no material
from the index patient is available, relatives of patients
with SMA, and spouses.
By analyzing 73 carriers and 42 noncarriers, we de-
termined the validity of the test. A major problem,which
affected the validity of the test, is the existence of chro-
mosomes carrying two SMN1 copies (4%) and the dif-
ficulty of distinguishing between one and two SMN1
copies in ∼6% of carriers and noncarriers (overlapping
interval ). The latter disadvantage0.60 ! SSMN1 ! 0.75
might be overcome by use of methods based on real-
time ongoing quantitative measurements, such as the
TAQMAN system. However, we will present the prac-
tical implications and limitations based on our nonra-
dioactive dosage assay, specifying for each group the
factors that must be taken into consideration for risk
calculation.
Group 1.—Parents of patients with SMA, where no
material from the index patient is available. In some
cases in which the patients died and no direct molecular
genetic test was possible, the parents should be tested
for their carrier status, only if the diagnosis of SMA in
the child is typical according to the diagnostic criteria
of the International SMA consortium. If both parents
show a heterozygous state, the SMA diagnosis of the
patient is most likely and a reliable prenatal diagnosis
can be offered. When the patient had a typical SMA and
only one parent is DSMN1 heterozygous, the other par-
ent has a 45% chance of carrying an intragenic muta-
tion. If the intragenic mutation is identified, a prenatal
diagnosis can be offered. If both parents show at least
two SMN1 copies, it is extremely unlikely that the af-
fected child had a 5q-SMA and it is advised to refrain
from prenatal diagnosis.
Group 2.—Relatives of patients with SMA who show
homozygous absence of SMN1. This category includes
relatives such as sibs, aunts, or uncles who have a high
a priori risk of being a carrier (risk to offspring 11:400,
justifying prenatal testing). Use of the D7SMN1 hetero-
zygosity test in relatives of patients with SMA will pro-
duce a false-negative or uncertain result due to two
SMN1 copies per chromosome and SSMN1 values
within the overlapping interval in ∼10%. However, if
the relative turns out to be a carrier (SSMN1 values
0.60), the spouse should be tested for further risk
calculation.
Although carrier testing is a helpful technique andmay
even be improved by methods that may allow a 100%
distinction between one and two SMN1 copies, it leads
to a 4% false-negative result rate because of carrierswith
two SMN1 copies per chromosome. The only way to
overcome this drawback is by linkage analysis. Unfor-
tunately, this is more expensive, requires testing of more
family members, and is not always feasible.
Group 3.—Spouses of carriers or patients with SMA.
A large number of prenatal diagnoses are currently un-
dertaken in low-risk constellations because heterozy-
gosity screening of spouses is not available. For example,
there is a statistical risk for an affected child of 1:200
(carriers) and 1:100 (patients), given a carrier frequency
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of 1:50 in the normal population, which leads to pre-
natal diagnoses in most pregnancies. With the possibility
of heterozygosity testing, a spouse showing at least two
SMN1 copies with an SSMN1 value 0.75 has 96%
probability of being a noncarrier (taking into consid-
eration the frequency of two SMN1 copies and theo-
retically of subtle mutations), and thus the probability
of being heterozygous can be reduced to !1:1,000. In
this case prenatal diagnostic testing should no longer be
performed. If an individual shows SSMN1 values within
the overlapping interval, the posterior probabilities
should be calculated by discriminant analysis, also tak-
ing into consideration the a priori risk for each individ-
ual. Because of the relatively small sample size, we have
not undertaken this approach. Further studies and a
larger sample size are therefore needed.
It is not useful to investigate parents of patients with
homozygous absence of SMN1 who wish to know
whether they are carriers by this quantitative test. On
the basis of a 2% de novo mutation frequency in SMA
patients (Wirth et al. 1997), 1% of SMA parents are not
carriers of SMA. About 90% of SMA parents will show
a gene dosage corresponding to one SMN1 copy, and
one can assume that they are carriers. Because the per-
centage of SMA parents for whom knowledge about
their noncarrier status would be important is 1%, and
thus far below the efficiency of the test (10% false-neg-
ative rate or, with improved techniques, 4%), the het-
erozygosity test would have no practical consequences
and should not be offered. Furthermore, other risk fac-
tors, such as germ-line mosaicism (Campbell et al. 1998)
have to be considered, and, therefore, it is very difficult
to release a family with one carrier and an affected child
from further prenatal testing. On the other hand, a direct
SMN test of the fetus would always provide a highly
reliable molecular diagnosis. Our data, obtained from
SMN1 dosage screening and searching for intragenic
SMN1 mutations in a collective of patients with well-
defined SMA, provide the first reliable basis for risk cal-
culations in families with SMA and will become an im-
portant diagnostic tool for genetic counseling.
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